- Home
- CMPX vs SCPH Comparison
CMPX vs SCPH Comparison
Compare CMPX & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- SCPH
- Stock Information
- Founded
- CMPX 2014
- SCPH 2013
- Country
- CMPX United States
- SCPH United States
- Employees
- CMPX N/A
- SCPH N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- SCPH Health Care
- Exchange
- CMPX Nasdaq
- SCPH Nasdaq
- Market Cap
- CMPX 291.8M
- SCPH 299.0M
- IPO Year
- CMPX N/A
- SCPH 2017
- Fundamental
- Price
- CMPX $3.71
- SCPH $5.63
- Analyst Decision
- CMPX Strong Buy
- SCPH Buy
- Analyst Count
- CMPX 8
- SCPH 3
- Target Price
- CMPX $13.50
- SCPH $12.00
- AVG Volume (30 Days)
- CMPX 978.2K
- SCPH 2.3M
- Earning Date
- CMPX 11-11-2025
- SCPH 11-12-2025
- Dividend Yield
- CMPX N/A
- SCPH N/A
- EPS Growth
- CMPX N/A
- SCPH N/A
- EPS
- CMPX N/A
- SCPH N/A
- Revenue
- CMPX N/A
- SCPH $49,969,000.00
- Revenue This Year
- CMPX N/A
- SCPH $108.95
- Revenue Next Year
- CMPX N/A
- SCPH $78.30
- P/E Ratio
- CMPX N/A
- SCPH N/A
- Revenue Growth
- CMPX N/A
- SCPH 107.79
- 52 Week Low
- CMPX $1.27
- SCPH $1.94
- 52 Week High
- CMPX $4.08
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- CMPX 70.95
- SCPH 63.78
- Support Level
- CMPX $3.37
- SCPH $4.33
- Resistance Level
- CMPX $3.70
- SCPH $5.62
- Average True Range (ATR)
- CMPX 0.19
- SCPH 0.04
- MACD
- CMPX 0.03
- SCPH -0.00
- Stochastic Oscillator
- CMPX 89.78
- SCPH 86.21
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.